Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients - Wikidata - awgldk - TriplyDB

Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients

Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients

http://www.wikidata.org/entity/Q24810279

about

CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen CYP2D6 genotype and tamoxifen response.CYP2D6 variants and the prediction of tamoxifen response in randomized patients: author response Impact of CYP2D*6 in the adjuvant treatment of breast cancer patients with tamoxifen Sulfotransferase genetic variation: from cancer risk to treatment response CYP2D6 genotyping and tamoxifen: an unfinished story in the quest for personalized medicine.Implication of Xenobiotic Metabolizing Enzyme gene (CYP2E1, CYP2C19, CYP2D6, mEH and NAT2) polymorphisms in breast carcinoma Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer The Impact of CYP2D6 Genotyping on Tamoxifen Treatment Tailoring adjuvant endocrine therapy for postmenopausal breast cancer: a CYP2D6 multiple-genotype-based modeling analysis and validation.PharmGKB summary: tamoxifen pathway, pharmacokinetics Coprescription of tamoxifen and medications that inhibit CYP2D6.Expectations, validity, and reality in pharmacogenetics.Genotype-guided tamoxifen therapy: time to pause for reflection?Clinical Relevance of CYP2D6 Genetics for Tamoxifen Response in Breast Cancer.Tamoxifen and CYP2D6: a contradiction of data.The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer SULT1A1 rs9282861 polymorphism-a potential modifier of efficacy of the systemic adjuvant therapy in breast cancer?Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients Novel pathway analysis of genomic polymorphism-cancer risk interaction in the Breast Cancer Prevention Trial.Determination of CYP2D6 *3, *4, and *10 frequency in women with breast cancer in São Luís, Brazil, and its association with prognostic factors and disease-free survival.CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark.Adjuvant hormonal therapy in premenopausal women with operable breast cancer: not-so-peripheral perspectives Expression of sulfotransferase isoform 1A1 (SULT1A1) in breast cancer cells significantly increases 4-hydroxytamoxifen-induced apoptosis Breast cancer: a neglected disease for the majority of affected women worldwide Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen CYP2D6 genotype and tamoxifen response for breast cancer: a systematic review and meta-analysis.Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy Clinical epidemiology and pharmacology of CYP2D6 inhibition related to breast cancer outcomes.Pharmacogenetics and breast cancer endocrine therapy: CYP2D6 as a predictive factor for tamoxifen metabolism and drug response?Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study.Pharmacogenetics of SULT1A1 Evaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for breast cancer chemoprevention: results from the NSABP P1 and P2 clinical trials.Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism.The effects of endoxifen and other major metabolites of tamoxifen on the sulfation of estradiol catalyzed by human cytosolic sulfotransferases hSULT1E1 and hSULT1A1*1 SULT1A1, CYP2C19 and disease-free survival in early breast cancer patients receiving tamoxifen.Pharmacogenetic testing affects choice of therapy among women considering tamoxifen treatment Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen.Relationships between CYP2D6 phenotype, breast cancer and hot flushes in women at high risk of breast cancer receiving prophylactic tamoxifen: results from the IBIS-I trial.

P2860

Q21195205-24482EDB-55FB-437C-BC25-C1A4B15A77B8 Q24813762-762F3CE8-F8DE-4AD0-9A80-78C626159382 Q25257685-52F76421-844F-4414-BD15-FD8937F4E29D Q27026180-A61E3E1E-F08B-4012-955F-56207212EA50 Q27027019-39F7DA62-AD39-4F44-A88E-8333964A3725 Q30400967-14EB5F13-A5D7-4A44-B8EC-2534706850D6 Q33329272-6FC62564-8AFF-45E0-854A-14010CFB4677 Q33611502-E4B85ECA-A3A7-41E1-84F5-4B80D838195B Q33664433-40A65BCC-CC6C-405F-AEEC-ED30C8723AEE Q33781027-391465AD-31DF-45E8-8F19-80BEC05566A1 Q33855494-FCBC8D7E-633C-4921-9D0F-F6CA6BEC16E3 Q33898184-10257C50-9B8F-4729-B284-A2E64011CFE2 Q33926313-E425B930-6A08-4AE1-9359-A2BEE0DD2B2D Q33955759-B6C5CBF0-D292-4F98-9E12-BBD004A43EC4 Q34095909-2D605266-F88F-414F-B1E0-35E5BC12977E Q34244463-0499106F-4E1F-4D6B-A75E-263F667B5E81 Q34253646-73EDD45C-6CBE-4496-9528-A2DDE15D9BB2 Q34307873-ACB96213-F01C-491A-BC79-194C5BAE94C6 Q34346501-B710E4CB-FDD6-4DC9-8C91-E21CD629E015 Q34386787-1273BA12-8920-4378-88EA-1B1977E86295 Q34502648-7DE275D4-D20B-48CB-9E39-D43856BDA12D Q34677193-238679B5-608D-4241-B60B-736B9240181B Q34774649-36FE8BC8-6915-45C6-88A2-8848980D7371 Q34793924-163704F5-6C68-497D-B237-80689FB0B575 Q34949553-1A67FB2A-C28C-44EA-95C8-415BD880B00A Q35006860-4A6D81E9-7C8C-4838-A4C8-9B4E50139233 Q35009604-27BE83A3-BB7F-4F52-8447-8AF1B10E8125 Q35056229-6386E6E1-6650-4E99-99DF-98D2EA222D0E Q35058455-02D38066-80C4-43E7-BA18-2A52D184192E Q35097430-6AD640F9-6420-49E3-8996-F8763B32107D Q35172199-4FD979A0-5A92-4273-B4D7-AB038D7BFAB5 Q35183173-E40AA62F-85CC-4FDD-AF7C-E3DA9B70E3A2 Q35510803-B60FD093-0F8A-4F71-A1ED-846FEDA23FDD Q35584977-A23D5003-9008-466B-A2DB-646E9EF713B3 Q35600254-CB9FDDE4-A0FC-4FD7-A477-CC5B658AE4D6 Q35605304-BF980A08-5433-49FD-AF1B-B210BE195416 Q35617340-63673767-3F55-44DA-9D0B-D72B1A8CB996 Q35749331-9CF5B729-96AB-4DA9-AC77-B3B25BCF4B3E Q35884159-23437499-A2A2-47A5-A52D-CD583880AD77 Q36090022-694DABD5-1914-441F-967F-0216F9E7D3AD

P2860

Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients

http://www.wikidata.org/entity/Q24810279

description

2005 nî lūn-bûn

@nan

2005 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Genotype of metabolic enzymes ...... opausal breast cancer patients

@ast

Genotype of metabolic enzymes ...... opausal breast cancer patients

@en

Genotype of metabolic enzymes ...... opausal breast cancer patients

@nl

type

label

Genotype of metabolic enzymes ...... opausal breast cancer patients

@ast

Genotype of metabolic enzymes ...... opausal breast cancer patients

@en

Genotype of metabolic enzymes ...... opausal breast cancer patients

@nl

prefLabel

Genotype of metabolic enzymes ...... opausal breast cancer patients

@ast

Genotype of metabolic enzymes ...... opausal breast cancer patients

@en

Genotype of metabolic enzymes ...... opausal breast cancer patients

@nl

P1433

Q24810279-F4A51B75-E823-4057-9C63-AC41F4C954A5

P1476

Q24810279-01099B3F-C855-46A3-843D-7D693EF2F1C3

P2093

Q24810279-21BB5818-71A2-4B5E-B71D-856520644B5F

Q24810279-53F37921-2875-4FEB-BC06-924FBD198A53

Q24810279-6F798B26-900F-4DE4-916D-618470189CB9

Q24810279-89FE79B7-B589-40D3-8946-9775CB9CD3D4

Q24810279-8F0CF372-B26E-4C99-BF1C-76E31056BA69

Q24810279-C89896D0-7BEA-4DF9-A05B-EE3E9440750C

Q24810279-E2503F71-2657-4602-81B9-E0848CB2946C

P2860

Q24810279-01C39CF9-DDA3-4852-9E06-CCE21F678BDA

Q24810279-0B37CA8F-1635-416A-97DA-D22A588645B8

Q24810279-0CFE709E-4057-4C29-83AB-F246684AF671

Q24810279-125DC8E4-A1A6-493B-A9E3-EFC280291E15

Q24810279-176D680E-277D-4EC0-9C45-CF34AB5468DD

Q24810279-478094F0-DB78-4F10-84EE-DAA912882172

Q24810279-49AA8A93-6B58-480D-BEB3-CB4B7C748D89

Q24810279-5A2CEFB3-B537-433A-936A-1856D81F59EC

Q24810279-60130D30-B0F8-47D9-8B16-A9C89E1D25F3

Q24810279-656EAAB5-A938-4A62-9CC9-CFE836E56818

P2888

Q24810279-129E1A95-197C-4B23-99DA-114D32661F3C

P304

Q24810279-DD04CF3B-89C1-4D39-9416-A5A5C11E3999

P31

Q24810279-3A7A317F-37E3-45B7-951E-792DF28D30EE

P356

Q24810279-4C730EEC-8159-4BF6-9BF5-2B8018CF7B3D

P407

Q24810279-10CFEAB9-F16E-4D1E-918C-E67023D0C65C

P433

Q24810279-820B88CE-3F9B-4CAB-A06E-DBEB0F09F1A4

P478

Q24810279-03CAF1F1-13C1-44FB-9BE9-DC5C6283D77C

P577

Q24810279-09324129-892A-495D-8066-F10D7D28BB42

P5875

Q24810279-E24E5984-E3FC-4611-82ED-C44884F659A3

P6179

Q24810279-CE936FB3-60C4-439F-8DBB-C1C4AE121AC7

P698

Q24810279-F2DD4B52-7836-4B93-9261-82440249409E

P921

Q24810279-B54C06F7-68AC-4C53-9322-FEDC87BADCA5

Q24810279-FF171AFA-D5C2-44E1-954F-64B0984F13EC

P932

Q24810279-DE3C3AE1-D305-4A64-8584-F6E944C83437

P356

P1433

Breast Cancer Research

P1476

Genotype of metabolic enzymes ...... opausal breast cancer patients

@en

P2093

Bo Nordenskjöld

http://www.w3.org/2001/XMLSchema#string

Lambert Skoog

http://www.w3.org/2001/XMLSchema#string

Lars-Erik Rutqvist

http://www.w3.org/2001/XMLSchema#string

Linda Vainikka

http://www.w3.org/2001/XMLSchema#string

Olle Stål

http://www.w3.org/2001/XMLSchema#string

Pia Wegman

http://www.w3.org/2001/XMLSchema#string

Sten Wingren

http://www.w3.org/2001/XMLSchema#string

P2860

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

Identification of human CYP forms involved in the activation of tamoxifen and irreversible binding to DNA.

CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants.

Steroid sulfation by expressed human cytosolic sulfotransferases.

Endocrine-responsive breast cancer and strategies for combating resistance.

The human CYP2D locus associated with a common genetic defect in drug oxidation: a G1934----A base change in intron 3 of a mutant CYP2D6 allele results in an aberrant 3' splice recognition site

Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences.

The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver.

Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells.

CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver.

P2888

P304

R284-90

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/BCR993

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2005-01-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7757367

http://www.w3.org/2001/XMLSchema#string

P6179

1027583948

http://www.w3.org/2001/XMLSchema#string

P698

15987423

http://www.w3.org/2001/XMLSchema#string

P921

P932

1143572

http://www.w3.org/2001/XMLSchema#string